MUMBAI, India, Nov. 21 -- Intellectual Property India has published a patent application (202547085523 A) filed by Obvia Pharmaceuticals, Ltd., Madison, U.S.A., on Sept. 9, for 'diagnosis, monitoring, and treatment of conditions characterized by intracellular free radicals.'
Inventor(s) include Fahl, William; Goesch, Torsten; Goesch, Hannah, Rebecca; and Goesch, Sarah, Ricarda.
The application for the patent was published on Nov. 21, under issue no. 47/2025.
According to the abstract released by the Intellectual Property India: "The invention features the use of coelenterazine, or a close analog, as a systemically administered real-time reporter of ROS or RNS levels in animal cell and organ settings. This real-time measurement can then be used to assess severity of free radical-dependent disease states, such as neurodegenerative diseases, post-organ transplant ischemia-reperfusion injury, acute radiation syndrome injury, and many others. The method can include real-time measurement of the therapeutic efficacy of PrC-210 as a free radical-scavenger capable of detoxifying both oxygen and nitrogen free radicals."
The patent application was internationally filed on Feb. 09, 2024, under International application No.PCT/US2024/015107.
Disclaimer: Curated by HT Syndication.
